产品
编 号：F166298
分子式：C46H72N10O15S
分子量：1037.19
分子式：C46H72N10O15S
分子量：1037.19
产品类型
规格
价格
是否有货
结构图
CAS No: 1447799-33-8
产品详情
生物活性：
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
体内研究：
Reltecimod (1.25-5 mg/kg; i.v.) 可提高感染不同细菌的小鼠的存活率。Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)
Dosage:1.25 or 5 mg/kg
Administration:i.v.; single dosage; at 4 h post infection
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)
Dosage:2.5 or 5 mg/kg
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model]
Dosage:1.25, 2.5, or 5 mg/kg
Administration:i.v.; single dosage
Result:Increased day 7 survival by up to 100%.
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
体内研究：
Reltecimod (1.25-5 mg/kg; i.v.) 可提高感染不同细菌的小鼠的存活率。Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)
Dosage:1.25 or 5 mg/kg
Administration:i.v.; single dosage; at 4 h post infection
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)
Dosage:2.5 or 5 mg/kg
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model]
Dosage:1.25, 2.5, or 5 mg/kg
Administration:i.v.; single dosage
Result:Increased day 7 survival by up to 100%.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备